Section Arrow
AKTS.NASDAQ
- Aktis Oncology Inc
Quotes are at least 15-min delayed:2026/03/10 01:07 EDT
Regular Hours
Last
 19.06
+0.25 (+1.33%)
Day High 
19.67 
Prev. Close
18.81 
1-M High
21.63 
Volume 
254.45K 
Bid
18.45
Ask
19.5
Day Low
18.259 
Open
19.3 
1-M Low
16.8 
Market Cap 
1.04B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 19.91 
20-SMA 19.08 
50-SMA -- 
52-W High 29.16 
52-W Low 16.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.15/--
Enterprise Value
1.05B
Balance Sheet
Book Value Per Share
-2.40
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.49M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ANTXAN2 Therapeutics5.25+2.41+84.86%-- 
RLMDRelmada Therapeutics7.17+2.72+61.12%-- 
IOVAIovance Biotherapeutics5.41+0.275+5.36%-- 
IBRXImmunityBio8.45-0.2-2.31%-- 
QNCXQuince Therapeutics0.1065+0.0042+4.11%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.